FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients

FDA Sets PDUFA Target Action Date of Feb. 3, 2018 THOUSAND OAKS, Calif., June 19, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the XGEVA® (denos... Biopharmaceuticals, Oncology, FDA Amgen, XGEVA, denosumab, Multiple Myeloma

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2042660

Source: HSMN NewsFeed - June 19, 2017 Category: Pharmaceuticals Source Type: news